Karyopharm Therapeutics (KPTI) Misses Q1 EPS by 251c

Karyopharm Therapeutics (NASDAQ: KPTI) reported Q1 EPS of ($2.77), $2.51 worse than the analyst estimate of ($0.26). Revenue for the quarter came in at $30.01 million versus the consensus estimate of $37.84 million.

For earnings history and earnings-related data on Karyopharm Therapeutics (KPTI) click here.

You May Also Be Interested In

• OpenAI: after the Hugging Face incident, we committed to conducting a much broader review of actions taken by our models
• OpenAI says its agents leaked some user images - Reuters
• Northrop Grumman wins $143M in new U.S. defense contracts